Elimination of highly multidrug-resistant wound bacteria by the lactic acid bacterial drug candidate ILP100
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
The rise and spread of antibiotic resistance poses a global threat, further exacerbated by geopolitical conflicts. Limosilactobacillus reuteri genetically modified to produce human CXCL12 (ILP100) has previously been shown to accelerate wound healing. Here, we report that ILP100 has potent bactericidal effects against MDR wound pathogens isolated from Ukrainian war victims, suggesting ILP100 as an important therapeutic alternative for eradication of MDR infections, while shortening the time to fully healed.
